Cakiroglu, YigitSaltik, AyseYuceturk, AysenKaraosmanoglu, OzgeKopuk, Sule YildirimScott Jr., Richard T.Tiras, BulentSeli, Emre2023-02-212023-02-212020-01-0110.18632/aging.103403https://hdl.handle.net/11443/2216http://dx.doi.org/10.18632/aging.103403We aimed to determine whether intraovarian injection of autologous platelet rich plasma (PRP) improves response to ovarian stimulation and in vitro fertilization (IVF) outcome in women with primary ovarian insufficiency (PO1). Women (N=311age 24-40) diagnosed with POI based on ESHRE criteria underwent intraovarian PRP injection. Markers of ovarian reserve, and IVF outcome parameters were followed. PRP treatment resulted in increased antral follicle count (AFC) and serum antimullerian hormone (AMH), while serum follicle stimulating hormone (FSH) did not change significantly. After PRP injection, 23 women (7.4\%) conceived spontaneously, 201 (64.8\%) developed antral follicle(s) and attempted IVF, and 87 (27.8\%) had no antral follicles and therefore did not receive additional treatment. Among the 201 women who attempted IVF, 82 (26.4\% of total) developed embryos25 of these women preferred to cryopreserve embryos for transfer at a later stage, while 57 underwent embryo transfer resulting in 13 pregnancies (22.8\% per transfer, 4\% of total). In total, of the 311 women treated with PRP, 25 (8.0\%) achieved livebirth/sustained implantation (spontaneously or after IVF), while another 25 (8.0\%) cryopreserved embryos. Our findings suggest that in women with POI, intraovarian injection of autologous PRP might be considered as an alternative experimental treatment option.primary ovarian insufficiencyplatelet rich plasmaPRPin vitro fertilizationArticleWOS:000540580800016